Study on clinical effects and recurrence of fleroxacin for the treatment of complicated urinary tract infections

T. Matsumoto; J. Kumazawa; K. Takahashi; T. Takesue; A. Yamaguchi; K. Tatsugami; H. Kawano; Y. Sakamoto; H. Kuramoto; K. Takayama; Y. Mihara; M. Kano; S. Andoh; K. Itoh; T. Matsui; S. Kamidono; S. Ka; M. Kominami; M. Hazama; Y. Hasunuma; H. Ohoka; A. Hayashi; A. Takenaka; N. Kataoka; M. Sugimoto; H. Miyazaki; I. Nakamura; H. Tanaka; K. Minayoshi; K. Tanaka; K. Umezu; M. Shinozaki; I. Tsuzi; N. Ito; Y. Nakano; H. Chokyu; M. Harada; Y. Nakagawa; K. Kikuchi; H. Akaza; K. Koiso; M. Ohtani; F. Manabe; S. Saito; F. Kondo; M. Tomobe; R. Noguchi; S. Yoshii; A. Tsuruta; S. Ishikawa; M. Tsutsumi; Y. Sawae

Study on clinical effects and recurrence of fleroxacin for the treatment of complicated urinary tract infections

T. Matsumoto, J. Kumazawa, K. Takahashi, T. Takesue, A. Yamaguchi, K. Tatsugami, H. Kawano, Y. Sakamoto, H. Kuramoto, K. Takayama, Y. Mihara, M. Kano, S. Andoh, K. Itoh, T. Matsui, S. Kamidono, S. Ka, M. Kominami, M. Hazama, Y. HasunumaH. Ohoka, A. Hayashi, A. Takenaka, N. Kataoka, M. Sugimoto, H. Miyazaki, I. Nakamura, H. Tanaka, K. Minayoshi, K. Tanaka, K. Umezu, M. Shinozaki, I. Tsuzi, N. Ito, Y. Nakano, H. Chokyu, M. Harada, Y. Nakagawa, K. Kikuchi, H. Akaza, K. Koiso, M. Ohtani, F. Manabe, S. Saito, F. Kondo, M. Tomobe, R. Noguchi, S. Yoshii, A. Tsuruta, S. Ishikawa, M. Tsutsumi, Y. Sawae

Research output: Contribution to journal › Article › peer-review

Abstract

Fleroxacin (FLRX) was given orally at 200mg once daily for 7 days to 218 patients with non-catheterized complicated urinary tract infections. The overall clinical efficacy rate according to the criteria proposed by the Japanese UTI Committee, was 75.4% (129/171). 129 patients who had been evaluated as excellent or moderate following initial treatment with FLRX, were assigned randomly to 3 groups. Group A was not treated. Group B was treated with 100mg of FLRX once daily for 28 days, and Group C was treated with 100mg of FLRX and clarithromycin (CAM) once daily for 28 days. With the occurrence of pyuria and bacteriuria as markers, the recurrence rates were 56.9%, 29.3% and 47.5% in Groups A, B, and C at 12 weeks, respectively, with no statistically significant difference. According to a breakdown of cases with bacteriuria only, the recurrence rates were 71.7%, 52.3% and 74.5% in Groups A, B and C respectively, with no statistically significant difference.

Original language	English
Pages (from-to)	567-576
Number of pages	10
Journal	Nishinihon Journal of Urology
Volume	60
Issue number	7
Publication status	Published - 1998
Externally published	Yes

All Science Journal Classification (ASJC) codes

Urology

Cite this

Matsumoto, T., Kumazawa, J., Takahashi, K., Takesue, T., Yamaguchi, A., Tatsugami, K., Kawano, H., Sakamoto, Y., Kuramoto, H., Takayama, K., Mihara, Y., Kano, M., Andoh, S., Itoh, K., Matsui, T., Kamidono, S., Ka, S., Kominami, M., Hazama, M., ... Sawae, Y. (1998). Study on clinical effects and recurrence of fleroxacin for the treatment of complicated urinary tract infections. Nishinihon Journal of Urology, 60(7), 567-576.

Matsumoto, T, Kumazawa, J, Takahashi, K, Takesue, T, Yamaguchi, A, Tatsugami, K, Kawano, H, Sakamoto, Y, Kuramoto, H, Takayama, K, Mihara, Y, Kano, M, Andoh, S, Itoh, K, Matsui, T, Kamidono, S, Ka, S, Kominami, M, Hazama, M, Hasunuma, Y, Ohoka, H, Hayashi, A, Takenaka, A, Kataoka, N, Sugimoto, M, Miyazaki, H, Nakamura, I, Tanaka, H, Minayoshi, K, Tanaka, K, Umezu, K, Shinozaki, M, Tsuzi, I, Ito, N, Nakano, Y, Chokyu, H, Harada, M, Nakagawa, Y, Kikuchi, K, Akaza, H, Koiso, K, Ohtani, M, Manabe, F, Saito, S, Kondo, F, Tomobe, M, Noguchi, R, Yoshii, S, Tsuruta, A, Ishikawa, S, Tsutsumi, M & Sawae, Y 1998, 'Study on clinical effects and recurrence of fleroxacin for the treatment of complicated urinary tract infections', Nishinihon Journal of Urology, vol. 60, no. 7, pp. 567-576.

@article{98ba0a4b40204632b4fd7fbb329ad03f,

title = "Study on clinical effects and recurrence of fleroxacin for the treatment of complicated urinary tract infections",

abstract = "Fleroxacin (FLRX) was given orally at 200mg once daily for 7 days to 218 patients with non-catheterized complicated urinary tract infections. The overall clinical efficacy rate according to the criteria proposed by the Japanese UTI Committee, was 75.4% (129/171). 129 patients who had been evaluated as excellent or moderate following initial treatment with FLRX, were assigned randomly to 3 groups. Group A was not treated. Group B was treated with 100mg of FLRX once daily for 28 days, and Group C was treated with 100mg of FLRX and clarithromycin (CAM) once daily for 28 days. With the occurrence of pyuria and bacteriuria as markers, the recurrence rates were 56.9%, 29.3% and 47.5% in Groups A, B, and C at 12 weeks, respectively, with no statistically significant difference. According to a breakdown of cases with bacteriuria only, the recurrence rates were 71.7%, 52.3% and 74.5% in Groups A, B and C respectively, with no statistically significant difference.",

author = "T. Matsumoto and J. Kumazawa and K. Takahashi and T. Takesue and A. Yamaguchi and K. Tatsugami and H. Kawano and Y. Sakamoto and H. Kuramoto and K. Takayama and Y. Mihara and M. Kano and S. Andoh and K. Itoh and T. Matsui and S. Kamidono and S. Ka and M. Kominami and M. Hazama and Y. Hasunuma and H. Ohoka and A. Hayashi and A. Takenaka and N. Kataoka and M. Sugimoto and H. Miyazaki and I. Nakamura and H. Tanaka and K. Minayoshi and K. Tanaka and K. Umezu and M. Shinozaki and I. Tsuzi and N. Ito and Y. Nakano and H. Chokyu and M. Harada and Y. Nakagawa and K. Kikuchi and H. Akaza and K. Koiso and M. Ohtani and F. Manabe and S. Saito and F. Kondo and M. Tomobe and R. Noguchi and S. Yoshii and A. Tsuruta and S. Ishikawa and M. Tsutsumi and Y. Sawae",

year = "1998",

language = "English",

volume = "60",

pages = "567--576",

journal = "Nishinihon Journal of Urology",

issn = "0029-0726",

publisher = "Kyushu University, Faculty of Science",

number = "7",

}

TY - JOUR

T1 - Study on clinical effects and recurrence of fleroxacin for the treatment of complicated urinary tract infections

AU - Matsumoto, T.

AU - Kumazawa, J.

AU - Takahashi, K.

AU - Takesue, T.

AU - Yamaguchi, A.

AU - Tatsugami, K.

AU - Kawano, H.

AU - Sakamoto, Y.

AU - Kuramoto, H.

AU - Takayama, K.

AU - Mihara, Y.

AU - Kano, M.

AU - Andoh, S.

AU - Itoh, K.

AU - Matsui, T.

AU - Kamidono, S.

AU - Ka, S.

AU - Kominami, M.

AU - Hazama, M.

AU - Hasunuma, Y.

AU - Ohoka, H.

AU - Hayashi, A.

AU - Takenaka, A.

AU - Kataoka, N.

AU - Sugimoto, M.

AU - Miyazaki, H.

AU - Nakamura, I.

AU - Tanaka, H.

AU - Minayoshi, K.

AU - Tanaka, K.

AU - Umezu, K.

AU - Shinozaki, M.

AU - Tsuzi, I.

AU - Ito, N.

AU - Nakano, Y.

AU - Chokyu, H.

AU - Harada, M.

AU - Nakagawa, Y.

AU - Kikuchi, K.

AU - Akaza, H.

AU - Koiso, K.

AU - Ohtani, M.

AU - Manabe, F.

AU - Saito, S.

AU - Kondo, F.

AU - Tomobe, M.

AU - Noguchi, R.

AU - Yoshii, S.

AU - Tsuruta, A.

AU - Ishikawa, S.

AU - Tsutsumi, M.

AU - Sawae, Y.

PY - 1998

Y1 - 1998

N2 - Fleroxacin (FLRX) was given orally at 200mg once daily for 7 days to 218 patients with non-catheterized complicated urinary tract infections. The overall clinical efficacy rate according to the criteria proposed by the Japanese UTI Committee, was 75.4% (129/171). 129 patients who had been evaluated as excellent or moderate following initial treatment with FLRX, were assigned randomly to 3 groups. Group A was not treated. Group B was treated with 100mg of FLRX once daily for 28 days, and Group C was treated with 100mg of FLRX and clarithromycin (CAM) once daily for 28 days. With the occurrence of pyuria and bacteriuria as markers, the recurrence rates were 56.9%, 29.3% and 47.5% in Groups A, B, and C at 12 weeks, respectively, with no statistically significant difference. According to a breakdown of cases with bacteriuria only, the recurrence rates were 71.7%, 52.3% and 74.5% in Groups A, B and C respectively, with no statistically significant difference.

AB - Fleroxacin (FLRX) was given orally at 200mg once daily for 7 days to 218 patients with non-catheterized complicated urinary tract infections. The overall clinical efficacy rate according to the criteria proposed by the Japanese UTI Committee, was 75.4% (129/171). 129 patients who had been evaluated as excellent or moderate following initial treatment with FLRX, were assigned randomly to 3 groups. Group A was not treated. Group B was treated with 100mg of FLRX once daily for 28 days, and Group C was treated with 100mg of FLRX and clarithromycin (CAM) once daily for 28 days. With the occurrence of pyuria and bacteriuria as markers, the recurrence rates were 56.9%, 29.3% and 47.5% in Groups A, B, and C at 12 weeks, respectively, with no statistically significant difference. According to a breakdown of cases with bacteriuria only, the recurrence rates were 71.7%, 52.3% and 74.5% in Groups A, B and C respectively, with no statistically significant difference.

UR - http://www.scopus.com/inward/record.url?scp=0031877476&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031877476&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0031877476

SN - 0029-0726

VL - 60

SP - 567

EP - 576

JO - Nishinihon Journal of Urology

JF - Nishinihon Journal of Urology

IS - 7

ER -

Study on clinical effects and recurrence of fleroxacin for the treatment of complicated urinary tract infections

Abstract

All Science Journal Classification (ASJC) codes

Other files and links

Fingerprint

Cite this